Advances in research of histone deacetylase inhibitors in treatment of hematological diseases

Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way. Key words: Histone deacetylase inhibitors; Hematologic neoplasms; Molecular targeted therapy; Chidamide; Treatment